GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US-China Biomedical Technology Inc (GREY:UCBB) » Definitions » 14-Day RSI

US-China Biomedical Technology (US-China Biomedical Technology) 14-Day RSI : N/A (As of Jun. 16, 2024)


View and export this data going back to 2011. Start your Free Trial

What is US-China Biomedical Technology 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-06-16), US-China Biomedical Technology's 14-Day RSI is N/A.

The industry rank for US-China Biomedical Technology's 14-Day RSI or its related term are showing as below:

UCBB's 14-Day RSI is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 46.04
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of US-China Biomedical Technology's 14-Day RSI

For the Health Information Services subindustry, US-China Biomedical Technology's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US-China Biomedical Technology's 14-Day RSI Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, US-China Biomedical Technology's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where US-China Biomedical Technology's 14-Day RSI falls into.



US-China Biomedical Technology  (GREY:UCBB) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US-China Biomedical Technology  (GREY:UCBB) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


US-China Biomedical Technology 14-Day RSI Related Terms

Thank you for viewing the detailed overview of US-China Biomedical Technology's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


US-China Biomedical Technology (US-China Biomedical Technology) Business Description

Traded in Other Exchanges
N/A
Address
2 Park Plaza, Suite 400, Irvine, CA, USA, 92614
US-China Biomedical Technology Inc is an early stage biomedical technology and services company. It is engaged in the integration and development of synergistic relationships with high profiled doctors and hospitals that will act as a bridge for connecting patients and bio-technology advances in China with its network of US based doctors and hospitals. It provides services for moving patients from China to the US with an emphasis on the demographics including pre-screening and genetic testing for family members of cancer patients, patients suffering from Diabetes, and general medical services including preventative care and physicals.

US-China Biomedical Technology (US-China Biomedical Technology) Headlines

No Headlines